ACR Convergence 2023

November 10-15, 2023. San Diego, CA.

View by Number View by Title View Sessions

Abstract Number: 0459

Upadacitinib Monotherapy versus Methotrexate in Patients with Rheumatoid Arthritis: Efficacy and Safety Through 5 Years in the SELECT-EARLY Randomized Controlled Trial
Abstract Number: 0460

Knowledge Related to Fertility and Infertility Treatments Among Women with Systemic Rheumatic Disease
Abstract Number: 0461

Self-esteem as a Determinant of Sexual Function in SLE Patients
Abstract Number: 0462

Breastfeeding Intention in Systemic Lupus Erythematosus Patients
Abstract Number: 0463

Appropriate Preconception Care Improves Pregnancy Outcomes in SLE Patients
Abstract Number: 0464

Adverse Pregnancy Outcomes in Sjogren’s Disease Compared to Controls: An Interdisciplinary Approach with Maternal Fetal Medicine
Abstract Number: 0465

The Effects of Post-Dobbs Abortion Policy on Rheumatology Clinical Practice: A Survey of Rheumatologists
Abstract Number: 0466

Impact of Postpartum on Patients with Inflammatory Rheumatic Diseases: The P2Rheum Study
Abstract Number: 0467

Cardiovascular Events During Pregnancy: Implications for Adverse Pregnancy Outcomes in Individuals with Autoimmune Rheumatic Diseases and Antiphospholipid Syndrome
Abstract Number: 0468

Patients with Autoimmune Skin Diseases Are at Increased Risk of Adverse Pregnancy Outcomes
Abstract Number: 0469

Hydroxychloroquine and Preeclampsia Risk in Lupus Pregnancy: Results from a Large Regional Integrated Health Network
Abstract Number: 0470

Educational Intervention to Increase Contraception Screening and Documentation for Reproductive-Aged Women Seen in an Academic Rheumatology Clinic
Abstract Number: 0471

Knowledge and Misconceptions About Contraception Among Individuals with Inflammatory Arthritis and Lupus-like Diseases
Abstract Number: 0472

Contraception Choices in Individuals with Inflammatory Arthritis and Lupus-like Disease Differ Based on Diagnosis and Teratogen Use
Abstract Number: 0473

The Number of Rheumatoid Arthritis Patients Who Give up Pregnancy Due to the Disease Is Decreasing

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].